Interesting and informative abstract on the future advancements in therapy. Here's an excerpt with tilsotolimod being mentioned:
The future of combination therapies in advanced melanoma
Tilsotolimod (IMO-2125) is a synthetic oligonucleotide which binds to TLR9 and activates antigen presentation of dendritic cells and macrophages with subsequent proliferation of antigen specific cytotoxic T lymphocytes (CD8+ T‑cells) in both injected and uninjected tumors. Tilsotolimod was tested in a phase I/II study in combination with ipilimumab in 26 PD‑1 refractory melanoma patients (NCT02644967). An ORR of 38% with 9.5% CRs was observed which exceeds the expected response rate to ipilimumab alone and the combination was well tolerated . A phase III study with this combination in comparison to ipilimumab alone in PD‑1 refractory patients is ongoing (NCT03445533).